Bigal Marcelo's Form 4/A amendment
AmendedPacira BioSciences, Inc. (PCRX) · filed Aug 13, 2024
- Accession no.
- 0001396814-24-000110
- Filed
- Aug 13, 2024
- Trade date
- Aug 12, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
- Original filed
- Aug 12, 2024
This filing lists 1 non-derivative transaction. Open-market purchases total $40.8K. It was filed 1 day after the trade.
This amendment replaces 0001396814-24-000106 (filed Aug 12, 2024).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bigal MarceloCIK 0001996637 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 12, 2024 | Common Stock | PPurchaseAcquired | +3,400 | $12.01F1 | +$40,834 | 8,630 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.75 to $12.35, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote 1.
Referenced by the price of 1 transaction in Table I.
Remarks
This Amended Form 4 is being filed solely to correct typographical errors in Footnote 1 of the original Form 4 which inadvertently referenced shares being sold rather than purchased.